Share your story and shine at JK Monitor!🌟 Welcome to JK Monitor, where every story matters and every achievement is celebrated! We invite you to share the remarkable journey of your life and showcase your accomplishments to the world. Join our exclusive interviews that honor exceptional individuals just like you. CHANDIGARH: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953) today announced the successful completion of its Graduation Ceremony 2025, held in alignment with the National Skill Development Corporation (NSDC), with 150 employees graduating from structured skilling and capability-building programmes across multiple Skill Sector Councils. The graduating cohort comprised employees certified under the Life Sciences Sector Skill Development Council (LSSSDC), Tourism & Hospitality Skill Council (THSC), Management & Entrepreneurship and Professional Skills Council (MEPSC), and the Banking, Financial Services and Insurance Sector Skill Council (BFSI SSC).
A measure focused on developing a workforce that is industry ready for both present and future, the initiative underlines the company’s focus to support India’s drive for global pharmaceutical leadership while aligning with national priorities including the Skill India Mission, Atmanirbhar Bharat, and the National Education Policy (NEP) 2020.
Reinforcing Venus Remedies’ approach to embedding structured learning frameworks into its long-term talent and capability development strategy, Akshansh Chaudhary, Executive Director and Chief Technical Officer, Venus Remedies, said, “Our engagement with NSDC reflects our long-term vision of integrating technology, talent, and structured learning. This initiative goes beyond certification. It is about enabling our people to think, lead, and innovate in a rapidly transforming pharmaceutical landscape. By fostering a culture of continuous upskilling, we are strengthening individual growth while building organisational resilience for the future.”
Themed “Empowering Growth with a Future Ready Workforce”, the graduation ceremony symbolised a key step in Venus Remedies’ journey to embed capability building, continuous learning, and performance excellence across its operations. Employees from multiple functions, including quality assurance, research and development, and corporate roles, participated in the programme, strengthening competencies in line with evolving pharmaceutical industry standards.
To prepare employees for certification, Venus Remedies implemented focused learning interventions, including role-specific training modules, assessment readiness programmes, and mentorship-led knowledge sharing. The outcomes of these assessments are being leveraged to identify skill gaps, strengthen succession planning, and design targeted development pathways aligned with future leadership and business needs.
The graduation ceremony served as a culmination of these efforts, designed to recognise achievement, instil pride, and inspire wider participation in ongoing learning initiatives. By formally celebrating skill acquisition, the company reinforced its belief that people development is central to healthcare excellence.
About Venus Remedies Ltd (venusremedies.com)
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.
Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.